JP2023540228A5 - - Google Patents

Info

Publication number
JP2023540228A5
JP2023540228A5 JP2023513401A JP2023513401A JP2023540228A5 JP 2023540228 A5 JP2023540228 A5 JP 2023540228A5 JP 2023513401 A JP2023513401 A JP 2023513401A JP 2023513401 A JP2023513401 A JP 2023513401A JP 2023540228 A5 JP2023540228 A5 JP 2023540228A5
Authority
JP
Japan
Application number
JP2023513401A
Other languages
Japanese (ja)
Other versions
JPWO2022042630A5 (https=
JP2023540228A (ja
JP7837952B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/114676 external-priority patent/WO2022042630A1/en
Publication of JP2023540228A publication Critical patent/JP2023540228A/ja
Publication of JP2023540228A5 publication Critical patent/JP2023540228A5/ja
Publication of JPWO2022042630A5 publication Critical patent/JPWO2022042630A5/ja
Application granted granted Critical
Publication of JP7837952B2 publication Critical patent/JP7837952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023513401A 2020-08-26 2021-08-26 ヘテロアリール基化合物、その製造方法および使用 Active JP7837952B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/111302 2020-08-26
CN2020111302 2020-08-26
CN2021075781 2021-02-07
CNPCT/CN2021/075781 2021-02-07
PCT/CN2021/114676 WO2022042630A1 (en) 2020-08-26 2021-08-26 Heteroaryl compounds, preparation methods and uses thereof

Publications (4)

Publication Number Publication Date
JP2023540228A JP2023540228A (ja) 2023-09-22
JP2023540228A5 true JP2023540228A5 (https=) 2024-08-28
JPWO2022042630A5 JPWO2022042630A5 (https=) 2024-08-28
JP7837952B2 JP7837952B2 (ja) 2026-03-31

Family

ID=80354683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513401A Active JP7837952B2 (ja) 2020-08-26 2021-08-26 ヘテロアリール基化合物、その製造方法および使用

Country Status (5)

Country Link
US (1) US20230357233A1 (https=)
EP (1) EP4204412A4 (https=)
JP (1) JP7837952B2 (https=)
CN (1) CN115968286A (https=)
WO (1) WO2022042630A1 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
EP4182313A4 (en) * 2020-07-16 2024-10-09 Mirati Therapeutics, Inc. KRAS-G12D INHIBITORS
WO2022170999A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 吡啶[4,3-d]嘧啶类化合物
CN116964058A (zh) * 2021-03-15 2023-10-27 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN115109078A (zh) * 2021-03-22 2022-09-27 苏州泽璟生物制药股份有限公司 嘧啶并吡啶类抑制剂及其制备方法和应用
CN115141215B (zh) * 2021-03-30 2023-09-15 上海德琪医药科技有限公司 Kras g12d蛋白抑制剂和其用途
WO2022206724A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
WO2022214102A1 (zh) * 2021-04-09 2022-10-13 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
CN115197245A (zh) * 2021-04-09 2022-10-18 上海拓界生物医药科技有限公司 一种Kras抑制剂及其制备方法
WO2022217042A1 (en) * 2021-04-09 2022-10-13 Ikena Oncology, Inc. Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
WO2022227987A1 (zh) * 2021-04-28 2022-11-03 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物,其制法与医药上的用途
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022236578A1 (en) * 2021-05-10 2022-11-17 Nikang Therapeutics, Inc. Exocyclic amino quinazoline derivatives as kras inhibitors
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物,及其制备和治疗用途
WO2022248885A2 (en) * 2021-05-28 2022-12-01 Redx Pharma Plc. Compounds
WO2022262686A1 (en) * 2021-06-13 2022-12-22 Jingrui Biopharma Co., Ltd. Kras g12d inhibitors
WO2022266015A1 (en) * 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
WO2023274324A1 (zh) * 2021-06-30 2023-01-05 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用
WO2023284881A1 (en) * 2021-07-16 2023-01-19 Silexon Ai Technology Co., Ltd. Heterocyclic compounds useful as kras g12d inhibitors
CN117157292A (zh) * 2021-07-16 2023-12-01 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
CN116669740A (zh) * 2021-08-16 2023-08-29 华润医药研究院(深圳)有限公司 嘧啶并吡啶类化合物及其制备方法和医药用途
TW202328124A (zh) * 2021-08-18 2023-07-16 大陸商北京加科思新藥研發有限公司 1,4-氧雜氮雜環庚烷衍生物及其用途
WO2023020521A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Pyridine fused pyrimidine derivatives and use thereof
WO2023020523A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Bicyclic derivatives and use thereof
CN116284055B (zh) * 2021-09-10 2025-09-23 润佳(苏州)医药科技有限公司 一种kras抑制剂及其用途
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
EP4417606A4 (en) * 2021-10-15 2025-10-22 Sunshine Lake Pharma Co Ltd NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
TW202334138A (zh) 2021-11-05 2023-09-01 美商新領域醫藥公司 癌症治療方法
CN117940436A (zh) * 2021-12-02 2024-04-26 上海和誉生物医药科技有限公司 一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用
CN116217591A (zh) * 2021-12-02 2023-06-06 思路迪生物医药(上海)有限公司 一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物
WO2023103523A1 (zh) * 2021-12-09 2023-06-15 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
EP4452974A4 (en) * 2021-12-21 2025-11-19 Bridgene Biosciences Inc RAS ONCOPROTEIN INHIBITORS
WO2023134465A1 (zh) * 2022-01-11 2023-07-20 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用
CN118556063A (zh) * 2022-01-21 2024-08-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
WO2023143312A1 (zh) * 2022-01-28 2023-08-03 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法及应用
AU2023218370B2 (en) 2022-02-09 2024-11-28 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN117659049A (zh) * 2022-08-23 2024-03-08 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
CN119317628A (zh) * 2022-03-22 2025-01-14 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
CN114573438A (zh) * 2022-03-31 2022-06-03 上海应用技术大学 一种单氟氯/溴代丙酮类化合物及其制备方法
CN119365459A (zh) * 2022-04-11 2025-01-24 杭州英创医药科技有限公司 作为kras g12d抑制剂的多环化合物
CN116891488B (zh) * 2022-04-11 2025-12-12 成都海博为药业有限公司 稠环化合物、包含其的药物组合物及应用
WO2023198191A1 (zh) * 2022-04-15 2023-10-19 杭州多域生物技术有限公司 一种六元并六元化合物、制备方法、药物组合物和应用
IL317601A (en) 2022-05-25 2025-02-01 Quanta Therapeutics Inc Pyrimidine-based modulators and their uses
WO2023246903A1 (zh) * 2022-06-24 2023-12-28 暨南大学 含硒杂环类化合物及其药用组合物和应用
WO2024008178A1 (zh) * 2022-07-08 2024-01-11 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
WO2024012519A1 (zh) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Pan-kras抑制剂
KR20250042155A (ko) 2022-07-27 2025-03-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 축합 고리계 화합물, 이의 제조 방법 및 이의 의학적 응용
CA3261681A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
CN120018863A (zh) * 2022-08-24 2025-05-16 珃诺生物医药科技(杭州)有限公司 用于调节kras(g12d)的方法和组合物
WO2024045066A1 (en) * 2022-08-31 2024-03-07 Nikang Therapeutics, Inc. Alkylidene carbamate as kras inhibitors
KR20250057027A (ko) * 2022-09-07 2025-04-28 브리스톨-마이어스 스큅 컴퍼니 Kras g12d 억제제
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024051852A1 (zh) * 2022-09-09 2024-03-14 上海翰森生物医药科技有限公司 含嘧啶多环类生物抑制剂、其制备方法和应用
CN120500484A (zh) * 2022-09-09 2025-08-15 珃诺生物医药科技(杭州)有限公司 作为用于治疗癌症的kras(g12d)突变型癌蛋白抑制剂的4-(3,8-二氮杂双环[3.2.1]辛烷-3-基)-7-萘-吡啶并[4,3-d]嘧啶衍生物
CN119855815A (zh) * 2022-09-21 2025-04-18 甘李药业股份有限公司 一种kras突变蛋白抑制剂、及其制备方法和应用
CN117800976A (zh) * 2022-09-30 2024-04-02 上海凌达生物医药有限公司 一类含氮杂环类化合物、制备方法和用途
CN117886833A (zh) * 2022-10-13 2024-04-16 广东东阳光药业股份有限公司 一种嘧啶并吡啶化合物、其药物组合物及其用途
JP2026504244A (ja) 2022-11-09 2026-02-04 レヴォリューション・メディスンズ,インコーポレイテッド 化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法
WO2024234360A1 (en) * 2023-05-18 2024-11-21 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
WO2024192424A1 (en) 2023-03-15 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2024215862A2 (en) * 2023-04-12 2024-10-17 Board Of Regents, The University Of Texas System Heterocyclic compounds as nras inhibitors
WO2024213122A1 (zh) * 2023-04-14 2024-10-17 广东东阳光药业股份有限公司 Kras抑制剂化合物、其药物组合物及其用途
WO2025002302A1 (zh) * 2023-06-28 2025-01-02 广东东阳光药业股份有限公司 嘧啶并吡啶化合物、其药物组合物及其用途
AU2024320375A1 (en) * 2023-08-08 2026-02-19 Lawrence Livermore National Security, Llc Fused pyridines for the treatment of cancer and other indications
TW202523324A (zh) * 2023-10-08 2025-06-16 大陸商成都海博為藥業有限公司 一種稠環化合物及應用
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
CN117683052A (zh) * 2023-12-07 2024-03-12 上海相辉医药科技有限公司 一种kras g12d抑制剂mrtx1133的制备方法
WO2025123318A1 (en) * 2023-12-15 2025-06-19 Shanghai Blueray Biopharma Co., Ltd. TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
PL1954699T3 (pl) * 2005-11-22 2013-01-31 Kudos Pharm Ltd Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
US10280172B2 (en) * 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
ES3060664T3 (en) * 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7516029B2 (ja) * 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
AU2019388998A1 (en) * 2018-11-29 2021-06-03 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
IL299344A (en) * 2020-06-25 2023-02-01 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2023540228A5 (https=)
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
CH718823A4 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)